Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05287022 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jun 2024 to Jun 2030 Completion date: Jun 2025 to Jun 2030 · Eligibility criteria expanded, about 32 wordsv2 Show 2 more changesShow less
    • Completion date: Jun 2025 to Jun 2030
    • Eligibility criteria expanded, about 32 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in the nasal passages and examine how often the results correlate with other tests currently done to make the diagnosis.
Trial Details
NCT Number NCT05287022
Lead Sponsor Arkansas Children's Hospital Research Institute
Conditions Primary Ciliary Dyskinesia
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov